Harmony Biosciences Announces Executive Appointments and Departures
Ticker: HRMY · Form: 8-K · Filed: Jul 1, 2024 · CIK: 1802665
| Field | Detail |
|---|---|
| Company | Harmony Biosciences Holdings, INC. (HRMY) |
| Form Type | 8-K |
| Filed Date | Jul 1, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, management
Related Tickers: HRMY
TL;DR
Harmony Bio shuffles execs: Dayno is new CMO, Simpson is CCO, Smith departs.
AI Summary
Harmony Biosciences Holdings, Inc. announced on June 27, 2024, a series of executive changes. Dr. Jeffrey M. Dayno has been appointed Chief Medical Officer, and Ms. Jennifer L. T. Simpson has been appointed Chief Commercial Officer. The company also announced the departure of Dr. Robert E. Smith as Chief Medical Officer, effective June 27, 2024.
Why It Matters
These executive changes could signal a shift in the company's strategic direction or operational focus, potentially impacting its drug development and commercialization efforts.
Risk Assessment
Risk Level: medium — Executive changes can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- Harmony Biosciences Holdings, Inc. (company) — Registrant
- Dr. Jeffrey M. Dayno (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. T. Simpson (person) — Appointed Chief Commercial Officer
- Dr. Robert E. Smith (person) — Departed Chief Medical Officer
- June 27, 2024 (date) — Effective date of changes
FAQ
Who has been appointed as the new Chief Medical Officer at Harmony Biosciences?
Dr. Jeffrey M. Dayno has been appointed as the new Chief Medical Officer.
Who has been appointed as the new Chief Commercial Officer?
Ms. Jennifer L. T. Simpson has been appointed as the new Chief Commercial Officer.
When did Dr. Robert E. Smith's departure as Chief Medical Officer become effective?
Dr. Robert E. Smith's departure as Chief Medical Officer became effective on June 27, 2024.
What is the exact name of the registrant filing this report?
The exact name of the registrant is Harmony Biosciences Holdings, Inc.
What is the state of incorporation for Harmony Biosciences Holdings, Inc.?
The state of incorporation for Harmony Biosciences Holdings, Inc. is Delaware.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-07-01 16:15:15
Key Financial Figures
- $0.00001 — ) on which registered Common Stock, $0.00001 par value per share HRMY The Nasdaq
Filing Documents
- hrmy-20240627x8k.htm (8-K) — 46KB
- 0001558370-24-009642.txt ( ) — 163KB
- hrmy-20240627.xsd (EX-101.SCH) — 3KB
- hrmy-20240627_lab.xml (EX-101.LAB) — 16KB
- hrmy-20240627_pre.xml (EX-101.PRE) — 10KB
- hrmy-20240627x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On July 1, 2024, the Company announced the change of the name of its wholly owned subsidiary from "Zynerba Pharmaceuticals, Inc." to "Harmony Biosciences Management, Inc." As of July 1, 2024, Zynerba Pharmaceuticals, Inc. is now known as Harmony Biosciences Management, Inc.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARMONY BIOSCIENCES HOLDINGS, INC. Date: July 1, 2024 By: /s/ Jeffrey M. Dayno Jeffrey M. Dayno President, Chief Executive Officer and Director